Chat with us, powered by LiveChat

Loading...

Irritable Bowel Syndrome Treatment Market Report

RA02136

Irritable Bowel Syndrome Treatment Market, by Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza, Others), Type (IBS-C, IBS-D): Global Opportunity Analysis and Industry Forecast, 2020-2027

RA02136

Pages: 195

Feb 2023

The global irritable bowel syndrome treatment market is estimated to surpass $2,176.8 million by 2027, exhibiting a CAGR of 8.2% from 2020 to 2027.

The report offers thorough analysis of the global irritable bowel syndrome treatment market by meticulously studying different aspects of the market including market dynamics, major segments, growth opportunities, regional market conditions, and leading players operating in the market.

This research report sheds a light on the current market scenario and upcoming trends & developments predicted to contribute for the global market growth during the forecast period. In addition, key market drivers and opportunities boosting the market growth are delivered in the report. Also, challenges and restraints that hold power to restrict the market growth are also offered in the report. Further, the report offers Porter’s five forces analysis of the market to elucidate factors such as bargaining power of suppliers & buyers, competitive landscape, threats of new players, and the occurrence of substitutes in the market.

The report offers future perspectives and growth outlook of the global irritable bowel syndrome treatment market that is based on the key forces molding the market. The report provides market size and forecast by keenly evaluating each segment of the global market. Regional market breakdown of these segments is also offered in the report. The report segments the global irritable bowel syndrome treatment market into four major regions including North America, Europe, Asia-Pacific, and LAMEA. Furthermore, these regions are sub-segmented to provide detailed panorama of the irritable bowel syndrome treatment market across major countries in specific regions. Moreover, the report includes some of the recent developments, trends, and future opportunities in each region.

Furthermore, the report highlights the major players functioning in the global irritable bowel syndrome treatment market. A detailed overview of top 10 players operating in the global irritable bowel syndrome treatment market is provided in the report for understanding their status and foothold over the market share. Company profile of each player includes several data points such as short overview of the company, major company executives, company’s financial status and revenue, major business strategies implemented by company, innovative developments or initiatives taken by company to shove their position and standout among other competitors in the global irritable bowel syndrome treatment market.

RESEARCH METHODOLOGY

Research Dive offers its clients extensive research and analysis gleaned from wide variety of factual inputs that largely includes interview with participants of the industry, reliable data & statistics, and regional intelligence. The in-house experts of the industry play a crucial role in designing analytic tools and models, tailor-made to the requests of an industry segment. The data and statistics are sterilized with these analytical tools and models, which enhances the accuracy of our advice and recommendations.

This research report is delivered by Research Dive by conducting long hours of discussions and interviews, with a broad range of stakeholders, which includes upstream and downstream participants. Our analysts have performed a mix of primary and secondary research for the market estimations and forecasts. A number of product type literatures, industry releases, annual reports, and other related documents of major participants of the industry have been reviewed, to better understand the global irritable bowel syndrome treatment market scenario. The initial phase of our in-depth study, where we perform wide-range data mining, referring to proficient & verified data sources such as independent studies, medical journals, technical journals, releases by trade association, materials published by government & regulatory authorities, and other.

KEY MARKET BENEFITS

  • The report is a compilation of detailed information, inputs from industry participants and industry experts across the value chain, and quantitative and qualitative assessment by industry analysts
  • This report provides in-depth analysis of current market trends, governing factors, macro-economic indicators from 2019 to 2027 to identify & understand the prevailing opportunities and the strategic assessment of the growth of the global irritable bowel syndrome treatment market
  • The report maps the qualitative sway of various industry factors on market segments as well as geographies
  • The market estimations and size provided in the report are based on a comprehensive analysis of recent & futuristic key developments in the irritable bowel syndrome treatment market
  • The growth and development strategies adopted by the prominent industry players are enlisted in the report to understand the competitive scenario of the irritable bowel syndrome treatment market

KEY MARKET SEGMENTS

The market has been studied based on the following segments:

  • Product: Xifaxan, Linzess/Constella, Viberzi, Amitiza, Others
  • Type: IBS-C, IBS-D

Region:

The global irritable bowel syndrome treatment market is divided into North America, Europe, Asia Pacific, and LAMEA.

The above-mentioned regions are further dived in countries as follows:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of LAMEA

KEY PLAYERS

The key players profiled in the report are Astellas Pharma, Inc., NextOmics, Genome Transcriptome Facility of Bordeaux, Ardelyx.

The report outlines the business overview including financial performance, latest strategic moves & developments, product portfolio, and SWOT analysis of the leading players of the irritable bowel syndrome treatment market.

    1. Ironwood Pharmaceuticals, Inc.

    2. Allergan

    3. Astellas Pharma, Inc.

    4. Takeda Pharmaceutical Company Limited

  • 1. RESEARCH METHODOLOGY

    • 1.1. Desk Research

    • 1.2. Real time insights and validation

    • 1.3. Forecast model

    • 1.4. Assumptions and forecast parameters

    • 1.5. Market size estimation

      • 1.5.1. Top-down approach

      • 1.5.2. Bottom-up approach

  • 2. REPORT SCOPE

    • 2.1. Market definition

    • 2.2. Key objectives of the study

    • 2.3. Report overview

    • 2.4. Market segmentation

    • 2.5. Overview of the impact of COVID-19 on Global Irritable Bowel Syndrome Treatment Market

  • 3. EXECUTIVE SUMMARY

  • 4. MARKET OVERVIEW

    • 4.1. Introduction

    • 4.2. Growth impact forces

      • 4.2.1. Drivers

      • 4.2.2. Restraints

      • 4.2.3. Opportunities

    • 4.3. Market value chain analysis

      • 4.3.1. List of raw material suppliers

      • 4.3.2. List of manufacturers

      • 4.3.3. List of distributors

    • 4.4. Innovation & sustainability matrices

      • 4.4.1. Technology matrix

      • 4.4.2. Regulatory matrix

    • 4.5. Porter’s five forces analysis

      • 4.5.1. Bargaining power of suppliers

      • 4.5.2. Bargaining power of consumers

      • 4.5.3. Threat of substitutes

      • 4.5.4. Threat of new entrants

      • 4.5.5. Competitive rivalry intensity

    • 4.6. PESTLE analysis

      • 4.6.1. Political

      • 4.6.2. Economical

      • 4.6.3. Social

      • 4.6.4. Technological

      • 4.6.5. Environmental

    • 4.7. Impact of COVID-19 on Irritable Bowel Syndrome Treatment Market

      • 4.7.1. Pre-covid market scenario

      • 4.7.2. Post-covid market scenario

  • 5. Irritable Bowel Syndrome Treatment Market, By Product

    • 5.1. Overview

    • 5.2 Xifaxan

      • 5.2.1 Definition, key trends, growth factors, and opportunities

      • 5.2.2 Market size analysis, by region, 2020-2027

      • 5.2.3 Market share analysis, by country, 2020-2027

    • 5.3 Linzess/Constella

      • 5.3.1 Definition, key trends, growth factors, and opportunities

      • 5.3.2 Market size analysis, by region, 2020-2027

      • 5.3.3 Market share analysis, by country, 2020-2027

    • 5.4 Viberzi

      • 5.4.1 Definition, key trends, growth factors, and opportunities

      • 5.4.2 Market size analysis, by region, 2020-2027

      • 5.4.3 Market share analysis, by country, 2020-2027

    • 5.5 Amitiza

      • 5.5.1 Definition, key trends, growth factors, and opportunities

      • 5.5.2 Market size analysis, by region, 2020-2027

      • 5.5.3 Market share analysis, by country, 2020-2027

    • 5.6 Others

      • 5.6.1 Definition, key trends, growth factors, and opportunities

      • 5.6.2 Market size analysis, by region, 2020-2027

      • 5.6.3 Market share analysis, by country, 2020-2027

    • 5.7 Research Dive Exclusive Insights

      • 5.7.1 Market attractiveness

      • 5.7.2 Competition heatmap

  • 6. Irritable Bowel Syndrome Treatment Market, By Distribution Channel

    • 6.1. Overview

    • 6.2 IBS-C

      • 6.2.1 Definition, key trends, growth factors, and opportunities

      • 6.2.2 Market size analysis, by region, 2020-2027

      • 6.2.3 Market share analysis, by country, 2020-2027

    • 6.3 IBS-D

      • 6.3.1 Definition, key trends, growth factors, and opportunities

      • 6.3.2 Market size analysis, by region, 2020-2027

      • 6.3.3 Market share analysis, by country, 2020-2027

    • 6.4 Research Dive Exclusive Insights

      • 6.4.1 Market attractiveness

      • 6.4.2 Competition heatmap

  • 7. Irritable Bowel Syndrome Treatment Market, By Region

    • 7.1 North America

      • 7.1.1 U.S

        • 7.1.1.1 Market size analysis, By Product, 2020-2027

        • 7.1.1.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.1.2 Canada

        • 7.1.2.1 Market size analysis, By Product, 2020-2027

        • 7.1.2.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.1.3 Mexico

        • 7.1.3.1 Market size analysis, By Product, 2020-2027

        • 7.1.3.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.1.4 Research Dive Exclusive Insights

        • 7.1.4.1 Market attractiveness

        • 7.1.4.2 Competition heatmap

    • 7.2 Europe

      • 7.2.1 Germany

        • 7.2.1.1 Market size analysis, By Product, 2020-2027

        • 7.2.1.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.2.2 UK

        • 7.2.2.1 Market size analysis, By Product, 2020-2027

        • 7.2.2.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.2.3 France

        • 7.2.3.1 Market size analysis, By Product, 2020-2027

        • 7.2.3.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.2.4 Spain

        • 7.2.4.1 Market size analysis, By Product, 2020-2027

        • 7.2.4.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.2.5 Italy

        • 7.2.5.1 Market size analysis, By Product, 2020-2027

        • 7.2.5.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.2.6 Rest of Europe

        • 7.2.6.1 Market size analysis, By Product, 2020-2027

        • 7.2.6.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.2.7 Research Dive Exclusive Insights

        • 7.2.7.1 Market attractiveness

        • 7.2.7.2 Competition heatmap

    • 7.3 Asia-Pacific

      • 7.3.1 China

        • 7.3.1.1 Market size analysis, By Product, 2020-2027

        • 7.3.1.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.3.2 Japan

        • 7.3.2.1 Market size analysis, By Product, 2020-2027

        • 7.3.2.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.3.3 India

        • 7.3.3.1 Market size analysis, By Product, 2020-2027

        • 7.3.3.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.3.4 Australia

        • 7.3.4.1 Market size analysis, By Product, 2020-2027

        • 7.3.4.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.3.5 South Korea

        • 7.3.5.1 Market size analysis, By Product, 2020-2027

        • 7.3.5.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.3.6 Rest of Asia-Pacific

        • 7.3.6.1 Market size analysis, By Product, 2020-2027

        • 7.3.6.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.3.7 Research Dive Exclusive Insights

        • 7.3.7.1 Market attractiveness

        • 7.3.7.2 Competition heatmap

    • 7.4 LAMEA

      • 7.4.1 Brazil

        • 7.4.1.1 Market size analysis, By Product, 2020-2027

        • 7.4.1.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.4.2 Saudi Arabia

        • 7.4.2.1 Market size analysis, By Product, 2020-2027

        • 7.4.2.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.4.3 UAE

        • 7.4.3.1 Market size analysis, By Product, 2020-2027

        • 7.4.3.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.4.4 South Africa

        • 7.4.4.1 Market size analysis, By Product, 2020-2027

        • 7.4.4.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.4.5 Rest of LAMEA

        • 7.4.5.1 Market size analysis, By Product, 2020-2027

        • 7.4.5.2 Market size analysis, By Distribution Channel, 2020-2027

      • 7.4.6 Research Dive Exclusive Insights

        • 7.4.6.1 Market attractiveness

        • 7.4.6.2 Competition heatmap

  • 8. Competitive Landscape

    • 8.1 Top winning strategies, 2020-2027

      • 8.1.1 By strategy

      • 8.1.2 By year

    • 8.2 Strategic overview

    • 8.3 Market share analysis, 2020-2027

  • 9. Company Profiles

    • 9.1 Ironwood Pharmaceuticals, Inc.

      • 9.1.1 Overview

      • 9.1.2 Business segments

      • 9.1.3 Product portfolio

      • 9.1.4 Financial performance

      • 9.1.5 Recent developments

      • 9.1.6 SWOT analysis

    • 9.2 Allergan

      • 9.2.1 Overview

      • 9.2.2 Business segments

      • 9.2.3 Product portfolio

      • 9.2.4 Financial performance

      • 9.2.5 Recent developments

      • 9.2.6 SWOT analysis

    • 9.3 Astellas Pharma, Inc.

      • 9.3.1 Overview

      • 9.3.2 Business segments

      • 9.3.3 Product portfolio

      • 9.3.4 Financial performance

      • 9.3.5 Recent developments

      • 9.3.6 SWOT analysis

    • 9.4 Takeda Pharmaceutical Company Limited AstraZeneca

      • 9.4.1 Overview

      • 9.4.2 Business segments

      • 9.4.3 Product portfolio

      • 9.4.4 Financial performance

      • 9.4.5 Recent developments

      • 9.4.6 SWOT analysis

    • 9.5 Sebela Pharmaceuticals Inc.

      • 9.5.1 Overview

      • 9.5.2 Business segments

      • 9.5.3 Product portfolio

      • 9.5.4 Financial performance

      • 9.5.5 Recent developments

      • 9.5.6 SWOT analysis

    • 9.6 Synergy Pharmaceuticals In. Bausch Health

      • 9.6.1 Overview

      • 9.6.2 Business segments

      • 9.6.3 Product portfolio

      • 9.6.4 Financial performance

      • 9.6.5 Recent developments

      • 9.6.6 SWOT analysis

    • 9.7 Synthetic Biologics

      • 9.7.1 Overview

      • 9.7.2 Business segments

      • 9.7.3 Product portfolio

      • 9.7.4 Financial performance

      • 9.7.5 Recent developments

      • 9.7.6 SWOT analysis

    • 9.8 Inc.

      • 9.8.1 Overview

      • 9.8.2 Business segments

      • 9.8.3 Product portfolio

      • 9.8.4 Financial performance

      • 9.8.5 Recent developments

      • 9.8.6 SWOT analysis

    • 9.9 Ardelyx

      • 9.9.1 Overview

      • 9.9.2 Business segments

      • 9.9.3 Product portfolio

      • 9.9.4 Financial performance

      • 9.9.5 Recent developments

      • 9.9.6 SWOT analysis

    • 9.10 Genome Transcriptome Facility of Bordeaux

      • 9.10.1 Overview

      • 9.10.2 Business segments

      • 9.10.3 Product portfolio

      • 9.10.4 Financial performance

      • 9.10.5 Recent developments

      • 9.10.6 SWOT analysis

    • 9.11 NextOmics

      • 9.11.1 Overview

      • 9.11.2 Business segments

      • 9.11.3 Product portfolio

      • 9.11.4 Financial performance

      • 9.11.5 Recent developments

      • 9.11.6 SWOT analysis

    • 9.12 and Takara Bio

      • 9.12.1 Overview

      • 9.12.2 Business segments

      • 9.12.3 Product portfolio

      • 9.12.4 Financial performance

      • 9.12.5 Recent developments

      • 9.12.6 SWOT analysis

    • 9.13 Inc. Oxford Nanopore

      • 9.13.1 Overview

      • 9.13.2 Business segments

      • 9.13.3 Product portfolio

      • 9.13.4 Financial performance

      • 9.13.5 Recent developments

      • 9.13.6 SWOT analysis

    • 9.14 Pacific Biosciences.

      • 9.14.1 Overview

      • 9.14.2 Business segments

      • 9.14.3 Product portfolio

      • 9.14.4 Financial performance

      • 9.14.5 Recent developments

      • 9.14.6 SWOT analysis

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed